



Universiteit
Leiden
The Netherlands

Targeted therapy in oncology: mechanisms and toxicity

Steeghs, N.

Citation

Steeghs, N. (2009, November 24). *Targeted therapy in oncology: mechanisms and toxicity*. Retrieved from <https://hdl.handle.net/1887/14431>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14431>

Note: To cite this publication please use the final published version (if applicable).

10

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Neeltje Steeghs, MD¹
Ron H.J. Mathijssen, MD PhD²
Judith A.M. Wessels, PhD³
Anne-Joy de Graan²
Tahar van der Straaten, PhD³
Mariangela Mariani⁴
Bernard Laffranchi⁴
Silvia Comis⁴
Maja J.A. de Jonge, MD PhD²
Hans Gelderblom, MD PhD¹
Henk-Jan Guchelaar, MD PhD³

¹Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands;

²Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands; ³Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; ⁴ Nerviano Medical Sciences, Nerviano, Italy

Submitted

Abstract

Purpose

Danuserib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, B, and C. This explorative study aims to identify possible relationships between single nucleotide polymorphisms in genes coding for drug metabolizing enzymes and transporter proteins and clearance of danuserib, to clarify the interpatient variability in exposure. In addition, this study explores the relationship between target receptor polymorphisms and toxicity of danuserib.

Methods

For associations with clearance cancer patients treated in a phase I study were analyzed for *ABCB1*, *ABCG2* and *FMO3* polymorphisms. Association analyses between neutropenia and drug target receptors, including *KDR*, *RET*, *FLT3*, *FLT4*, *AURKB* and *AURKA*, were performed in patients treated at recommended phase II dose-levels in three danuserib phase I or phase II trials.

Results

For the *FMO3* 18281AA polymorphism, a significantly higher clearance was noticed, compared to patients carrying at least 1 wild type allele. For the other enzymes and transporters, no relationships between danuserib clearance and drug metabolizing enzymes and transporter protein polymorphisms were found. No effect of target receptor genotypes or haplotypes on neutropenia was observed.

Conclusions

The relationship between *FMO3* polymorphisms and clearance of danuserib warrants further research, as we could study only a relatively small and heterogeneous group of patients. However, as we did not find any major correlations between pharmacogenetic variability in the studied enzymes and transporters and pharmacokinetics nor toxicity, it is unlikely that danuserib is highly susceptible for pharmacogenetic variation. Therefore, no dosing alterations of danuserib are expected in the future, based on the polymorphisms studied here.

Introduction

Aurora kinases are serine/threonine kinases with a key role in mitosis.¹⁻⁹ Danusertib (PHA-739358) is a new active moiety in cancer treatment which selectively inhibits the ATP site of aurora-A (AURKA, $IC_{50} = 13$ nM), aurora-B (AURKB, $IC_{50} = 79$ nM) and aurora-C (AURKC, $IC_{50} = 61$ nM) kinases.^{10,11} Inhibition of aurora-A or aurora-B activity in tumor cells results in impaired chromosome alignment, weakening of the mitotic checkpoint, polyploidy, and subsequent cell death.^{12,13} Danusertib shows anti-tumor activity in a wide range of cancer cell lines and xenograft tumor models.¹⁰ Tested in a panel of 32 kinases, danusertib also showed increased affinity for multiple other kinases ($IC_{50} < 0.50$ μ M), including ret proto-oncogene (RET), vascular endothelial growth factor receptor 3 (FLT4, VEGFR3), and fms-related tyrosine kinase 3 (FLT3). Therefore, inhibition of these kinases may influence danusertib efficacy or toxicity in cancer patients.

The major route of metabolism of danusertib involves the formation of the N-oxide metabolite, mainly through the enzyme flavin containing monooxygenase 3 (FMO3), forming an inactive metabolite. Furthermore, danusertib was found to be a substrate for efflux proteins ATP-binding cassette B1 (ABCB1/MDR1) and G2 (ABCG2/BCRP) in *in vitro* studies (unpublished data). In addition, it has been shown that histone H3 is phosphorylated by aurora-B and phosphorylation of histone H3 is inhibited in skin, bone marrow and xenograft tumors after treatment with danusertib.¹⁰ As a consequence, the extent of histone H3 phosphorylation is studied as a pharmacodynamic biomarker of danusertib effectiveness.

Recently, this new compound has been introduced in human research. In a phase I study, performed at the Leiden University Medical Center, Leiden and the Erasmus University Medical Center, Rotterdam (The Netherlands), the pharmacokinetics of danusertib were characterized by relatively low to moderate plasma clearances (range 10-59 L/hour) and an elimination half-life of about 30 hours.¹⁴ Danusertib showed linear pharmacokinetics over the dose-range studied. At all dose levels, the inter-patient variability of the primary pharmacokinetic parameters of danusertib was remarkably high, with a coefficient of variation of 40-50%, which is in line with other anti-cancer drugs. Toxicity increased with danusertib dose. However, currently it is unclear whether pharmacogenetic variability in drug metabolizing or transporting proteins can explain a large part of the inter-individual variability in pharmacokinetics and/or toxicity-profile. Therefore, the current explorative study aims to identify possible (and clinically relevant) relationships between single-nucleotide polymorphisms (SNPs) in genes coding for drug metabolizing enzymes and for transporter proteins and pharmacokinetic parameters of danusertib. In this study we also explore the possible relationship between polymorphisms in genes encoding the drug target receptors and toxicity of danusertib.

Methods

This study was conducted on three different groups of patients. Group A consisted of patients enrolled into a phase I dose-escalating study of danusertib in patients with advanced or metastatic solid tumors. Group B and group C consisted both of subsets of patients enrolled into phase II studies of danusertib in patients with various tumor types, including breast cancer, pancreatic cancer, colorectal cancer, ovarian cancer, or hormone refractory prostate cancer.

From patients treated in the phase I study (Group A) residual blood samples were available for pharmacogenetic analyses to compare with pharmacokinetics (all patients) and toxicity (patients at the recommended phase II dose (RP2D)). Groups B and C consisted of patients treated in two ongoing phase II studies. They were all treated at the RP2D and had blood samples available for pharmacogenetic analysis to compare with toxicity.

Patients and samples

Eligibility criteria, drug administration procedures, safety, pharmacokinetic and efficacy methods as used in the phase I trial are described in detail elsewhere.¹⁴

Briefly, Group A patients had histologically or cytologically confirmed advanced or metastatic solid tumors for whom no standard therapy was available, with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 . Danusertib was administered intravenously on days 1, 8, 15 every 28 days. Doses were escalated from 45 mg/m² to 400 mg/m² in the 6-hour infusion schedule, and from 250 mg/m² to 330 mg/m² in the subsequent 3-hour infusion schedule. The trial had a standard 3+3 phase I dose escalation study design. In the phase II study from which group B patients were entered, men with metastatic hormone refractory prostate cancer, progressive after docetaxel treatment were eligible. Patients of group B were randomized between treatment with 330 mg/m² of danusertib on days 1, 8, 15 every 28 days in a 6-hour infusion schedule or with 500 mg/m² of danusertib on days 1 and 15 every 28 days in 24-hour infusion schedule according to the phase II study protocol. The total exposure in both groups is expected to be identical, and in line with the RP2D as determined in phase I studies.^{8,14} For group C, patients with several tumor types (see table 1), progressive after 1 or 2 lines of chemotherapy depending on tumor type were eligible. Treatment consisted of 500 mg/m² of danusertib on days 1 and 15 every 28 days in 24-hour infusion schedule. No pharmacokinetic analyses were performed in the phase II trials.

For all groups, patients were evaluated for adverse events and toxicity according to the National Cancer Institute Common Terminology Criteria (NCI-CTC), version 3.0. Response evaluation was performed every 2 cycles and was assessed according to RECIST 1.0.¹⁵

Table 1. Patient characteristics, danusertib induced toxicity in the first cycle, and pharmacokinetic/pharmacodynamic results.

Baseline characteristics	All patients n (%) N=63	Phase I patients n (%) N=48*	RP2D patients n (%) N=30**
Gender, male	43 (68)	35 (73)	20 (67)
Race, caucasian	62 (98)	47 (98)	29 (97)
Age, years			
Median (range)	58 (22-75)	58 (22-75)	60 (38-74)
Patient Group			
A (phase I)	48 (76)	48 (100)	15 (50)
B (phase II, prostate cancer)	7 (11)	–	7 (23)
C (phase II, various tumor types)	8 (13)	–	8 (27)
RP2D Group			
330 mg/m ² d1,8,15 every 4 weeks	20 (31)	15 (31)	20 (67)
500 mg/m ² d 1 and 15 every 4 weeks	10 (16)	–	10 (33)
Tumor type			
Colorectal cancer	19 (30)	18 (38)	10 (33)
Breast cancer	6 (10)	1 (2)	5 (17)
Esophageal cancer	4 (6)	4 (8)	2 (7)
Ovarian cancer	3 (5)	2 (4)	1 (3)
Pancreatic cancer	4 (6)	3 (6)	1 (3)
Prostate cancer	8 (13)	1 (2)	7 (23)
Miscellaneous	19 (30)	19 (39)	4 (13)
ECOG performance score			
0	15 (24)	8 (17)	11 (37)
1	48 (76)	40 (83)	19 (63)
Nr of previous treatment lines			
Median (range)	3 (0-12)	3 (0-12)	3 (1-7)
Toxicity during cycle 1			
Any toxicity grade 1-4	51 (81)	37 (77)	28 (93)
Any toxicity grade 3 or 4	22 (35)	15 (31)	15 (50)
Neutropenia grade 1-4	34 (54)	25 (52)	19 (63)
Neutropenia grade 3 or 4	18 (29)	12 (25)	13 (43)
Febrile neutropenia	1 (2)	1 (2)	1 (3)
Clearance day 1 cycle 1 (L/hour/m ²), n=47			
Median ± SD	n.a.	17.8 ± 5.8	n.a.
Histone H3 phosphorylation, n=28, Δ%			
Median ± SD	n.a.	-92.3 ± 13.1	n.a.
Number of treatment courses			
Median (range)	2 (1-31)	2 (1-31)	2 (1-15)

RP2D: Recommended phase 2 dose; ECOG: Eastern Cooperative Oncology Group; SD: standard deviation; Histone H3 phosphorylation: % change in number of positive cells by immunohistochemistry for Histone H3 phosphorylation, * One patient included in toxicity analyses, but no PK data available, **Fifteen patients of the phase I trial were treated at the RP2D level.

Residual blood samples taken for routine patient care were stored at -20°C at the local hospital laboratories. Of each patient, one frozen whole blood sample was collected from the two participating hospitals. All samples were anonymized by a third party, according to the instructions stated in the Codes for Proper Use and Proper Conduct (www.federa.org). Approval from the institutional medical ethical review boards was obtained prior to analysis.

Pharmacokinetic, toxicity and biomarker parameters

Pharmacokinetic (PK) evaluation was performed by collecting blood samples on days 1 to 4, day 8, days 15 to 18 and day 22 of cycle 1, and days 1 and 15 of cycles 2 and 4. Pharmacokinetic evaluation was carried out using a non-compartmental approach with the aid of WinNonlin software (version 3.1, Pharsight Inc., Mountain View, CA, USA). In this study, danusertib clearance (L/hour/m²) was selected as the pharmacokinetic parameter to associate with enzyme and transporter genetic polymorphisms. As mentioned in the phase I report, clearance was not influenced by duration of infusion and was comparable in both 3-hour and 6-hour infusion schedules; 16.2 and 18.0 L/hour/m² respectively.¹⁴ Clearances in our study were also comparable to mean danusertib clearance reported in another phase I study using even a 24-hour infusion schedule.⁸ Therefore, patients treated at both 3-hour and 6-hour infusion schedules were included in the pharmacokinetic association analyses.

The most frequent and clinically relevant danusertib induced side effects, known from phase I trials, are grade 3 and 4 neutropenia, defined as neutrophil counts 0.5-1.0*10⁹/L and <0.5*10⁹/L, respectively, and febrile neutropenia. These side-effects were therefore considered to be the best candidate toxicity parameters for the association analyses with drug target receptor genetic polymorphisms.

For the association analysis with neutropenia, we included patients treated at the RP2D (thus, 330 mg/m² days 1, 8, 15 q4w or 500 mg/m² days 1 and 15 q4w equivalent). Since grade 3-4 neutropenia was associated with danusertib dose, association analyses were performed with neutropenia developing in the first cycle only, excluding the effects of cumulative danusertib dose and dose reductions in subsequent cycles.¹⁴ The probability of grade 3 or 4 neutropenia in the first danusertib cycle was not influenced by infusion duration and this toxicity was also comparable in both used schedules.^{8,14} Therefore, for the purpose of analyzing associations between drug target receptor polymorphisms and neutropenia all patients treated at the RP2D were combined. Only one case of febrile neutropenia was observed, and as a result association analyses with febrile neutropenia could not be performed.

Skin biopsies for biomarker analysis (Group A) were performed at baseline, and

10 minutes before the end of the first infusion in the first cycle. As a biomarker for aurora-B inhibition, the inhibition of histone H3 phosphorylation in the skin was measured by immunohistochemistry.^{10,16,17} Change in histone H3 phosphorylation was used as parameter for association analyses with polymorphisms in the aurora-B receptor.

Selection of candidate genes

Candidate genes were selected based on the information of preclinical pharmacology studies as reported in the Investigator's brochure (Nerviano Medical Sciences on file). For association with clearance *ABCB1*, *ABCG2*, and *FMO3* were the genes selected. For correlation with danusertib toxicity selected genes were the drug target genes encoding *AURKA*, *AURKB*, *AURKC*, *C-ABL*, *NTRK1*, *RET*, *FGFR1*, *LCK*, *FLT4*, *C-KIT*, *KDR*, *CDK2A*, *STLK1*, and *FLT3*.

The single-nucleotide polymorphisms (SNPs) were selected, taking into consideration one or more of the following criteria: a validated SNP assay, SNP should preferably cause non-synonymous amino acid changes, an indication for clinical relevance should be available from previous publications, and the preferred minority genotype allele-frequency should be at least ~10% in Caucasians. For *ABCB1*, *ABCG2*, *FMO3*, *AURKA*, *AURKB*, *RET*, *FLT4*, *KDR*, and *FLT3*, one or multiple SNPs could be selected according to these criteria.

DNA extraction, SNP analysis, and haploblock selection

DNA was isolated from EDTA-blood samples with MagNA Pure Compact DNA Isolation kit (Roche Diagnostics, Almere, The Netherlands). DNA concentrations were quantified on the nanodrop (Isogen, IJsselstein, The Netherlands). From the patients of whom whole blood samples were unavailable, DNA was isolated from blood-serum with MagNA Pure Compact DNA Isolation kit. Taqman assays were obtained from Applied Biosystems (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). SNP genotyping was performed with the BIOMARK 48.⁴⁸ dynamic array (Fluidigm Corporation, South San Francisco, CA, USA). All assays were performed according to protocols provided by the manufacturer. As a quality control, 4 samples were genotyped in duplicate for all assays and 2 assays were tested in duplicate on all samples. As negative controls water was used. Overall, no inconsistencies in genotypes were observed. To genotype DNA extracted from blood serum on the Biomark, a pre-amplification step was necessary. Briefly, to 1.25 µl of serum-DNA a dilution of all taqman assays in a total volume of 1.25 µl and 2.5 µl of pre-amplification mastermix (Applied Biosystems) was added, and amplified on a conventional PCR machine. This mixture was 20x diluted and 2.5 µl was used in the Biomark conform their protocol.

Genotype distributions are presented in Table 2. The success rates for all genotyping analyses were 100%, except for RET 135G>A with 22% invalid results, despite repeated analyses. Genotype frequencies for 21 of 22 SNPs were in Hardy-Weinberg equilibrium ($P > 0.05$). KDR 1719A>T (rs1870377) was not in Hardy-Weinberg equilibrium which was most likely due to the limited population size. Our genotype frequencies were in line with previously reports and frequencies for Caucasians, as reported in the NCBI database (www.ncbi.nlm.nih.gov).

If linkage disequilibrium between SNPs was detected, haplotypes were set with gPLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>).¹⁸ No phase uncertainty in the defined haploblocks and haplotypes ($R^2 > 0.98$) was seen. The haploblock for *ABCB1* included 1236C>T, 2677G>A/T, and 3435C>T; the haploblock for *ABCG2* included 15994G>A, and 1143C>T; and the haploblock for *FMO3* included 15167G>A, 21443A>G, and 18281G>A (Table 4).

Statistical analysis

Differences in pharmacokinetic and pharmacodynamic parameters among genotypes were analyzed by the Student's *t*-test, or analysis of variance (ANOVA) for continuous variables or chi-square test for dichotomous variables, where appropriate. For toxicity, differences in genotype distribution were tested by 3×2 cross-tabulations for each genotype, and by 2×2 cross-tabulations for carriers versus noncarriers, with analysis by a two-sided chi-square test. Polymorphisms within a gene were tested with the chi-square test (P -value < 0.05) to detect linkage disequilibrium. Associations between the number of copies of a haplotype and clinical parameters were performed using a chi-square test for dichotomous variables and Student's *t*-test, ANOVA for continuous variables.

All statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL) and were two-sided, with a level of significance of $\alpha = 0.05$. Because of the explorative nature of this study, we did not perform a correction for multiple comparisons.

Results

Baseline patient characteristics, observed treatment-related toxicities, pharmacokinetics and treatment duration are presented in Table 1. Our population comprised 98% Caucasians with 68% males and 32% females. Most frequent tumor types were colorectal cancer (30%), prostate cancer (13%) and breast cancer (10%). Danusertib doses used ranged from 45 mg/m² to 500 mg/m², with infusion times of 3 (14%), 6 (70%) and 24 hours (16%), according to the designs of the mentioned phase I and phase II trials.

Table 2. Genotype frequency results.

Gene and Variant	No. Patients	p*	q**
ABCB1 1236C>T	63	0.556	0.444
ABCB1 2677G>A/T	63	0.563	0.437
ABCB1 3435C>T	63	0.484	0.516
ABCG2 421C>A	63	0.889	0.111
ABCG2 346G>A	63	0.952	0.048
ABCG2 1143C>T	63	0.770	0.230
ABCG2 15994G>A	63	0.690	0.310
FMO3 15167G>A	63	0.563	0.437
FMO3 21443A>G	63	0.794	0.206
FMO3 18281G>A	63	0.873	0.127
KDR -604T>C	63	0.508	0.492
KDR 1192G>A	63	0.921	0.079
KDR 1719A>T	63	0.254	0.746
KDR 54G>A	63	0.563	0.437
KDR -92G>A	63	0.762	0.238
RET 37412G>A	63	0.810	0.190
RET 135G>A	49	0.776	0.224
FLT3 738C>T	63	0.397	0.603
FLT4 1480A>G	63	0.881	0.119
AURKB 893G>A	63	0.889	0.111
AURKA 169G>A	63	0.778	0.222
AURKA 91A>T	63	0.778	0.222

*p: frequency of wild-type allele; **q: frequency of variant allele

Haplotype frequencies for *ABCB1* were GCC 0.443, TTT 0.412, GTC 0.096, and GCT 0.024, for *ABCG2* CC 0.691, TT 0.230, and TC 0.079, and for *FMO3* AGA 0.437, GGG 0.437, and GAG 0.127. Haploblock for *KDR* included -604 T>C, 1192G>A, and 1719A>T, for *RET* 37412G>A, and 135G>A, and for *AURKA* 169G>A, and 91A>T. Haplotype frequencies for *KDR* were TCT 0.410, CCT 0.316, CCA 0.109, TCA 0.087, CTA 0.047, CTT 0.021, and TTA 0.0114, for *RET* GG 0.602, and GA 0.938, and for *AURKA* GA 0.556, AA 0.222, and GT 0.222.

There was no apparent association between cycle 1 day 1 danusertib clearance

Table 4. Association between genetic polymorphisms and grade 3-4 neutropenia in cycle 1 in all patients at RP2D levels.

Gene	Polymorphism	Genotype	Total No. Patients	Neutropenia grade 3-4		p-value
				No	Yes	wt/wt vs wt/m vs m/m
<i>KDR</i>	-604T>C	TT	6	3	3	0.308
		TC	15	7	8	
		CC	9	7	2	
	1192G>A	GG	27	15	12	1.000
		GA	3	2	1	
	1719A>T	AA	1	0	1	0.426
		AT	15	8	7	
		TT	14	9	5	
	54G>A	GG	9	5	4	0.673
		GA	16	10	6	
		AA	5	2	3	
	-92G>A	AA	3	3	0	0.265
AG		7	4	3		
GG		20	10	10		
<i>RET</i>	37412G>A	GG	24	14	10	0.507
		GA	5	2	3	
		AA	1	1	0	
	135G>A 3 missing	GG	16	9	7	0.489
		GA	8	6	2	
		AA	3	1	2	
<i>FLT3</i>	738C>T	CC	5	4	1	0.414
		CT	15	7	8	
		TT	10	6	4	
<i>FLT4</i>	1480A>G	AA	23	12	11	0.427
		AG	7	5	2	
<i>AURKB</i>	893G>A	GG	22	11	11	0.407
		GA	8	6	2	
<i>AURKA</i>	169G>A	GG	18	10	8	0.672
		GA	11	6	5	
		AA	1	1	0	
	91A>T	AA	20	11	9	0.110
		AT	6	2	4	
		TT	4	4	0	

(L/hour/m²) and genetic polymorphisms in *ABCB1* or *ABCG2* (Table 3). However, for *FMO3*, patients carrying at least one G allele had a significantly slower clearance compared to the 18281 AA patients ($P = 0.017$).

No relationship between observed grade 3-4 neutropenia in the first treatment cycle and *KDR*, *RET*, *FLT3*, *FLT4*, *AURKB* or *AURKA* genotype was observed (Table 4). Also the *ABCB1*, *ABCG2*, and *FMO3* haplotypes did not show an association with danusertib clearance, nor did *KDR*, *RET*, *AURKA* haplotypes relate to danusertib induced grade 3-4 neutropenia (Table 5).

Also, no association was observed between the studied *AURKB* polymorphism and change in level of histone H3 phosphorylation induced by danusertib. The decrease in histone H3 phosphorylation for *AURKB* homozygous wild type genotypes (GG) was 91% (SD 13.3%), while the heterozygous genotype (GA) had a decrease of 84% (SD 12.2%, $P=0.223$).

Discussion

Aurora kinase inhibitors are relatively new and promising agents in development for anticancer treatment.¹⁻⁹ The current knowledge on treatment actions, toxicity, biomarkers and efficacy is still very limited. danusertib is the first aurora kinase inhibitor in which a pharmacogenetic pathway analysis has been performed to clarify pharmacokinetic and pharmacodynamic features of the drug.

In the last decade, well known examples of anti-cancer drugs can be given, for which initial recommended dose-levels had to be changed based on toxicity in subgroups of patients.¹⁹⁻²² These subgroups of patients, with in general decreased enzymatic function based on genetic polymorphisms, could have been identified earlier if pharmacogenetic knowledge was available at an earlier stage. Therefore, it is recognized more and more that pharmacogenetic research in the earliest stages of development of new anti-cancer agents is highly relevant. While the basic characteristics of the new agent have to become more clear, also selection of patients with potential increased toxicity, or decreased efficacy, should be performed as early as possible. Therefore, the decision was made not to delay the pharmacogenetic analyses till after registration of the compound, but to explore potentially clinical relevant pharmacogenetic variation at this stage of development.

Our study was conducted in patients of a recent phase I trial and subsets of two phase II trials of danusertib, and therefore patient numbers for both pharmacokinetic and pharmacodynamic association analyses are relatively limited. However, in the phase I trial DNA-data were available for almost the entire patient population, making selec-

Table 3. Association between genetic polymorphisms and danusertib clearance.

Gene	Polymorphism	Genotype	No. Patients	Clearance L/hour/m ² d1c1	
				Mean	SD
ABCB1	1236C>T	CC	16	17.8	6.5
		CT	21	18.3	5.9
		TT	10	18.6	4.9
			P-value		0.930
	2677G>A/T	GG	17	18.2	6.6
		GT	20	18.5	5.8
		TT	10	17.7	4.9
			P-value		0.948
	3435C>T	CC	13	19.5	6.1
		CT	21	17.7	5.9
		TT	13	17.8	5.6
			P-value		0.638
ABCG2	421C>A	CC	36	18.1	6.1
		CA	11	18.8	4.8
				P-value	
	346G>A	GG	45	18.2	5.9
		GA	2	18.6	5.2
				P-value	
	143C>T	CC	29	18.9	6.1
		CT	15	17.3	5.5
		TT	3	16.5	3.6
			P-value		0.537
	15994G>A	GG	23	18.5	5.0
		GA	21	18.2	6.2
AA		3	16.5	3.6	
		P-value		0.859	
FMO3	15167G>A	GG	15	19.5	6.6
		GA	20	18.1	6.0
		AA	12	16.9	4.2
			P-value		0.537
	21443A>G	AA	27	19.2	6.3
		AG	18	16.9	5.1
		GG	2	16.4	1.3
			P-value		0.382
	18281G>A	GG	35	18.1	5.2
		GA	11	17.2	6.1
		AA	1	34.0	n.a.
			P-value		0.017

n.a.: not applicable

Table 5. Haplotype analysis: uncorrected P values using Pearson χ^2 analysis, independent samples Student's t-test or one-way ANOVA where appropriate

Gene	SNPS	Haplotype	Neutropenia grade 3-4 p-value
KDR	-604T>C	TCT	0.146
	1192G>A	CCT	0.460
	1719A>T	CCA	1.000
RET	37412G>A	GG	0.773
	135G>A	GA	0.773
AURKA	169G>A	GA	0.205
	91A>T	AA	0.672
		GT	0.110
Gene	SNPS	Haplotype	clearance L/hour/m ² d1c1 p-value
ABCB1	1236C>T	GCC	0.953
	2677G>A/T	TTT	0.935
	3435C>T		
ABCG2	15994G>A	CC	0.859
	1143C>T	TT	0.588
FMO3	15167G>A	AGA	0.537
	21443A>G	GGG	0.603
	18281G>A	GAC	0.017

tion bias less likely. The two phase II trials are still ongoing and blood for DNA analysis was available for all patients included in the trials at the Erasmus University Medical Center at the moment of pharmacogenetic analyses.

A correlation between danusertib pharmacokinetics and pharmacogenetic variation is only seen for the FMO3 18281G>A homozygous variant and clearance. We can not exclude that this is the result of chance, but also for the other 2 SNPs (15167 G>A and 21443G>A) in this gene, a pattern to altered clearance, based on genotype, is suggested. As FMO3 is responsible for the main route of metabolism of danusertib, this warrants further research.

Currently, the mechanism causing neutropenia after danusertib treatment is unclear and could be associated with peak values (C_{max}) or threshold values. Based on the new pharmacogenetic data from our current analysis no predisposition for the severity of hematological toxicity could be identified.

Clearly, this study has its limitations. As described earlier, due to the phase I and II nature of the studies patient numbers were limited and the group is quite heterogeneous. The power to find statistical significant differences in genotype of haplotype analyses was limited.

That correlations between the main enzymes and transporters involved in danusertib metabolism, and pharmacokinetics and toxicity are absent, does not mean that these results are unimportant. This study outcome makes the chance that danusertib is highly susceptible to pharmacogenetic variation less probable. More discrete differences, based on pharmacogenetic variability, should be explored further in additional (population based) pharmacogenetic studies for this compound.²³⁻²⁵ The relatively high inter-individual variation observed could not be explained through pharmacogenetics and, for instance, the role of environmental factors might be important.

The reason for a lack of association between Histone H3 phosphorylation and the studied AURKB polymorphism is unclear. Whether the 893G>A mutation results in altered gene function is unknown.

Since danusertib is currently used in two treatment schedules, 330 mg/m² on days 1, 8 and 15 every 4 weeks and 500 mg/m² on days 1 and 15 every 4 weeks, a population based pharmacokinetic-pharmacogenetic model might help in selecting the optimal treatment schedule.²³⁻²⁵ A second advantage of a population based pharmacokinetic-pharmacogenetic model is that the relative impact of all individual SNPs as covariates can be explored.

In conclusion, in this explorative study no highly significant associations between polymorphisms in genes coding for drug metabolizing enzyme, for transporter proteins and clearance of danusertib, between target receptor polymorphisms and toxicity of danusertib and between polymorphisms in the aurora kinase B receptor and the extent of histone H3 phosphorylation were seen. Future studies, including analyses of more patients on danusertib treatment and the use of population based pharmacokinetic-pharmacogenetic models to select the optimal danusertib treatment schedule are planned.

Acknowledgements

We would like to acknowledge the contribution of Vincent Dezentje (Departments of Medical Oncology and Clinical Pharmacy and Toxicology LUMC) in anonymizing all data, Margret den Hollander and Jan Ouwerkerk (Department of Medical Oncology LUMC) for data and sample collection, Renee Baak-Pablo (Department of Clinical Pharmacy and Toxicology LUMC) for SNP analysis, and Ronald de Wit (Department of Medical Oncology EUMC) as principal investigator in the phase II prostate study.

References

1. Jones SF, Cohen RB, Dees EC, et al. Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase. *J Clin Oncol* 25:18s (suppl; abstr 3577) 2007.
2. Renshaw S, Patnaik A, Gordon M, et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. *J Clin Oncol* 25:18s (suppl; abstr 14130) 2007.
3. Rubin EH, Shapiro GI, Stein MN, et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. *J Clin Oncol* 24:18s (suppl; abstr 3009) 2006.
4. Schellens JH, Boss D, Witteveen PO, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. *J Clin Oncol* 24:18s (suppl; abstr 3008) 2006.
5. Foran JM, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. *J Clin Oncol* 26:18s (suppl; abstr 2518) 2008.
6. Jones SF, Burris HA, Dumez H, et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results. *J Clin Oncol* 26:18s (suppl; abstr 2517) 2008.
7. Robert F, Hurwitz H, Verschraegen CF, et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. *J Clin Oncol* 26:18s (suppl; abstr 14642) 2008.
8. Cohen RB, Jones SF, von Mehren M, et al. Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. *J Clin Oncol* 26:18s (suppl; abstr 2520) 2008.
9. Plummer ER, Calvert H, Arkenau H, et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. *J Clin Oncol* 26:18s (suppl; abstr 2519) 2008.
10. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. *Mol.Cancer Ther.* 2007;6:3158-68.
11. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. *J Med Chem.* 2006;49:7247-51.
12. Warner SL, Gray PJ, Von Hoff DD. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. *Semin.Oncol* 2006;33:436-48.
13. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. *Clin Cancer Res.* 2006;12:6869-75.
14. Steeghs N, Eskens F, Gelderblom H, et al. A Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor PHA-739358 in patients with advanced or metastatic solid tumors. *J Clin Oncol* in press 2009.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J.Natl.Cancer Inst.* 2000;92:205-16.
16. Soncini C, Carpinelli P, Gianellini L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. *Clin Cancer Res.* 2006;12:4080-9.
17. Camidge DR, Pemberton MN, Growcott JW, et al. Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. *Br.J Cancer* 2005;93:208-15.
18. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am.J.Hum.Genet.* 2007;81:559-75.
19. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. *PLoS.Med.* 2007;4:e209.
20. Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. *Br.J Cancer* 1998;77:497-500.
21. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. *Clin Pharmacol.Ther.* 2008;83:160-6.
22. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics.J* 2002;2:43-7.
23. Zwaveling J, Press RR, Bredius RG, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. *Ther.Drug Monit.* 2008;30:504-10.
24. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. *J Pharmacokinet.Biopharm.* 1992;20:511-28.
25. Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. *Clin Pharmacokinet.* 2008;47:487-513.

